Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown.
Innovo Therapeutics has raised $14.1M in total funding. The most recent round was Seed. The last funding was announced in December 2023.
Innovo Therapeutics's investors include CICC, Huajin Capital, Ming Bioventures, Longmen Capital, HMC Ventures.
Innovo Therapeutics is headquartered in San Diego, United States.
Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown.
Innovo Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Innovo Therapeutics — Funding & Investors." VCBacked, December 1, 2023, https://www.vcbacked.co/company/innovo-therapeutics. Accessed August 1, 2026.
VCBacked. (2023). Innovo Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/innovo-therapeutics
{{cite web |title=Innovo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/innovo-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated